<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386412</url>
  </required_header>
  <id_info>
    <org_study_id>2005-002813-19.</org_study_id>
    <secondary_id>TAMOVALCIR in alogenic</secondary_id>
    <nct_id>NCT00386412</nct_id>
  </id_info>
  <brief_title>TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant</brief_title>
  <official_title>Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <brief_summary>
    <textblock>
      PRINCIPAL ENDPOINT To value valganciclovir efficacy in advance treatment of CMV in patients
      received allogenic transplant with a uniform treatment.

      SECONDARY ENDPOINT To value valganciclovir security in advance treatment of CMV in in
      patients received allogenic transplant with a uniform treatment.

      The security will be valued by the % of patients that:

      Will have negative CMV Neutropenia &lt;1000 neutrophils/mm3 or &lt;500 neutrophils/mm3 in the first
      35 days of treatment - follow-up Renal toxicity in the first 35 days of treatment - follow-up
      (defined by elevated creatinine &gt;1mg/dL or twice the basal value) CMV illness during the
      treatment or in the next 2 months Blood Antigenemia / PCR positive in the next 2months of
      treatment

      This dates Hill be compared with a patients control group treated with intravenous
      valganciclovir
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial with a drug in new conditions of use
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To value valganciclovir efficacy in advance treatment of CMV in patients received allogenic transplant with a uniform treatment.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To value valganciclovir security in advance treatment of CMV in in patients received allogenic transplant with a uniform treatment.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years old

          -  Any patients with allogenic TPH

          -  Following in post-TPH with antigenemia or PCR-CMV

          -  CMV in blood test detected by antigenemia or PCR before the day 180 post-TPH

          -  The beginning of treatment must be Duch early as possible. Maximum in the 72 hours
             from the antigenemia or PCR-CMV detection

          -  Be the first or second time of a CMV infection

          -  Sign the informed consent

          -  Pregnancy negative test in fertile age patients

        Exclusion Criteria:

          -  Patients received auto or syngenic TPH

          -  Patients &lt;50 kg weight

          -  Known allergy or hypersensibility patients to valganciclovir, ganciclovir or aciclovir

          -  Digestive intolerant: nauseous, vomit and or diarrhea that could difficult oral
             administration of valganciclovir

          -  Patients that presents CMV infection or that is being evaluated for suspected CMV

          -  Patients that have presented &gt;2 CMV infection episode, before the current one

          -  Severe liver disease defined by bilirubin ≥ 10mg/dL

          -  Treated with: foscarnet, ganciclovir, cidofovir or another antiviral drug active to
             CMV, in the previous 30 days at the current episode

          -  Neutrophils &lt; 500 /µL at the beginning of valganciclovir treatment. Patients with &gt;500
             PMN/µL and &lt; 1000/µL must start a G-CSF treatment to get neutrophils value &gt; 1000/µL

          -  Platelets &lt; 25/mm3 even receiving transfusion

          -  Clearance Creatinine &lt; 10mL/min or dialysed patients

          -  Pregnancy or lactant women

          -  Other contraindication detailed in the &quot;filling card&quot;

          -  Previous inclusión in this study at the treated group. Is allowed that a patient
             participate as a control case and after that receive valganciclovir treatment in after
             CMV episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>de la Cámara Rafael, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico y Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Germans Trias i Pujol&quot;</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital general de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal, Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer, Murcia</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <reference>
    <citation>Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K; European Group for Blood and Marrow Transplantation. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004 Jun;33(11):1075-81.</citation>
    <PMID>15077131</PMID>
  </reference>
  <reference>
    <citation>Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, Webster A; Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002 Apr 15;99(8):3050-6.</citation>
    <PMID>11929799</PMID>
  </reference>
  <reference>
    <citation>Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002 Feb 15;99(4):1159-64.</citation>
    <PMID>11830461</PMID>
  </reference>
  <reference>
    <citation>Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. Review.</citation>
    <PMID>15482169</PMID>
  </reference>
  <reference>
    <citation>Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65(6):859-78. Review.</citation>
    <PMID>15819597</PMID>
  </reference>
  <reference>
    <citation>Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004 Apr;4(4):611-20.</citation>
    <PMID>15023154</PMID>
  </reference>
  <reference>
    <citation>Clark BS, Chang IF, Karpen SJ, Herrera L, Scott JD, Bristow LJ, Quirós-Tejeira RE, Goss JA. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation. 2004 May 15;77(9):1480.</citation>
    <PMID>15167619</PMID>
  </reference>
  <reference>
    <citation>Ciancio G, Burke GW, Mattiazzi A, Leibovici Z, Dowdy L, Roth D, Kupin W, Rosen A, Jorge D, Cirocco RE, Miller J. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant. 2004 Aug;18(4):402-6.</citation>
    <PMID>15233817</PMID>
  </reference>
  <reference>
    <citation>Einsele H, Reusser P, Hertenstein B, Bornhäuser M, Kröger N, Kahls P, et al. Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD. Blood 2004;104(11):abstract 2239.</citation>
  </reference>
  <reference>
    <citation>Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 Apr 15;34(8):1094-7. Epub 2002 Mar 11. Review.</citation>
    <PMID>11914998</PMID>
  </reference>
  <reference>
    <citation>Burri M, Wiltshire H, Kahlert C, Wouters G, Rudin C. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr Infect Dis J. 2004 Mar;23(3):263-6.</citation>
    <PMID>15014306</PMID>
  </reference>
  <reference>
    <citation>Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, Davis C, Boeckh M. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001 Feb 15;97(4):867-74.</citation>
    <PMID>11159510</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pethema</name_title>
    <organization>pethema</organization>
  </responsible_party>
  <keyword>Cytomegalovirus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

